Skip to contentN
Niagen Bioscience, Inc.
N
NAGENiagen Bioscience, Inc. Q1 2019 · 10-Q
Revenue$10.05M$10.05M+53.0% vs Q1 2018 Net Income-$8.34M-$8.34MN/M vs Q1 2018 EPS Diluted-$0.15-$0.15N/M vs Q1 2018 Gross Profit$5,301,000+69.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Niagen Bioscience, Inc. · CIK 1386570 · Engraved from SEC EDGAR
Operating Cash Flow-$3,048,000N/M Free Cash Flowderived-$3,287,000N/M Margins · derivedGross margin52.8%+5.0 pt vs Q1 2018
Operating margin-83.3%+44.6 pt vs Q1 2018
Net margin-83.0%+45.6 pt vs Q1 2018
ended Mar 31, 2019 · filed May 9, 2019 · 39 d after period end